MCID: VCC001
MIFTS: 50

Vaccinia

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 44 D014615
UMLS 72 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to viral infectious disease and eczema herpeticum, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Sorafenib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, prostate and skin, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 375)
# Related Disease Score Top Affiliating Genes
1 viral infectious disease 30.2 IRF7 IRF3 IL2 ERVW-1 EIF2AK2
2 eczema herpeticum 29.8 IRF7 IRF3
3 cowpox 11.7
4 smallpox 11.1
5 variola major 11.1
6 obsolete: small pox 10.9
7 herpes simplex 10.7
8 human immunodeficiency virus type 1 10.6
9 rabies 10.6
10 monkeypox 10.6
11 encephalitis 10.6
12 stomatitis 10.6
13 chromosome 2p16.1-p15 deletion syndrome 10.5 VRK2 BANF1
14 dermatitis 10.5
15 severe combined immunodeficiency 10.5
16 measles 10.5
17 immune deficiency disease 10.5
18 influenza 10.4
19 chickenpox 10.4
20 melanoma 10.4
21 dermatitis, atopic 10.4
22 cytokine deficiency 10.4
23 allergic hypersensitivity disease 10.4
24 avian influenza 10.4
25 colon adenocarcinoma 10.3
26 molluscum contagiosum 10.3
27 hepatitis c virus 10.3
28 fibroma 10.3
29 lymphocytic choriomeningitis 10.3
30 severe acute respiratory syndrome 10.3
31 glioma 10.3
32 glial tumor 10.3
33 keratitis, hereditary 10.3
34 polykaryocytosis inducer 10.3
35 pancreatic cancer 10.3
36 japanese encephalitis 10.3
37 skin disease 10.3
38 poliomyelitis 10.3
39 hepatitis b 10.2
40 murray valley encephalitis 10.2 IL2 ERVW-1
41 erythroleukemia, familial 10.2
42 triiodothyronine receptor auxiliary protein 10.2
43 kala-azar 1 10.2
44 squamous cell papilloma 10.2
45 hepatitis c 10.2
46 papilloma 10.2
47 newcastle disease 10.2
48 leishmaniasis 10.2
49 colorectal cancer 10.2
50 exanthem 10.2

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 AZI2 BTRC DUSP3 EIF2AK2 EPS15 IL2
2 immune system MP:0005387 9.32 AZI2 BTRC EIF2AK2 EPS15 IL2 IRF3

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
7
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
8
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 60843 446556
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Iron-Dextran Complex Phase 3
11 polysaccharide-K Phase 3
12 Immunologic Factors Phase 2, Phase 3
13 Angiogenesis Inhibitors Phase 2, Phase 3
14 Protein Kinase Inhibitors Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Antiviral Agents Phase 2, Phase 3
17 Antineoplastic Agents, Immunological Phase 2, Phase 3
18 Immunosuppressive Agents Phase 2, Phase 3
19 Antimetabolites, Antineoplastic Phase 2, Phase 3
20 Antimetabolites Phase 2, Phase 3
21 Angiogenesis Modulating Agents Phase 2, Phase 3
22 Albumin-Bound Paclitaxel Phase 2, Phase 3
23 Tubulin Modulators Phase 2, Phase 3
24 Antimitotic Agents Phase 2, Phase 3
25 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
26 Folic Acid Antagonists Phase 2, Phase 3
27 Vitamin B9 Phase 2, Phase 3
28 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
29 Vitamin B Complex Phase 2, Phase 3
30
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
31 Folate Phase 2, Phase 3
32
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 5310940 9887054 43805 6857599
33
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
34
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
35
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
36
Phenol Approved, Experimental Phase 2 108-95-2 996
37
Goserelin Approved Phase 2 65807-02-5, 1233494-97-7 47725 5311128
38
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
39
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
40
tannic acid Approved Phase 1, Phase 2 1401-55-4
41
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
42
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
43
Coal tar Approved Phase 1, Phase 2 8007-45-2
44
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
45
Testosterone Approved, Experimental, Investigational Phase 2 481-30-1, 58-22-0 6013 10204
46
Lenograstim Approved, Investigational Phase 2 135968-09-1
47
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
48
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
49
Metronidazole Approved Phase 2 443-48-1 4173
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 258)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Unknown status NCT01913353 Phase 3
5 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
6 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
7 The Clinical Study of Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
8 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
9 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543567 Phase 3
10 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543268 Phase 3
11 A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola Completed NCT02509494 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Recruiting NCT03699124 Phase 3
14 A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Active, not recruiting NCT02562755 Phase 3 Sorafenib
15 A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
16 A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Terminated NCT01383148 Phase 2, Phase 3 placebo
17 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
18 INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA Unknown status NCT00002817 Phase 1, Phase 2
19 A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers Unknown status NCT02425241 Phase 1, Phase 2 CPHPC
20 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
21 A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma. Completed NCT01394939 Phase 1, Phase 2 Irinotecan
22 Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
23 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
24 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
25 Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
26 A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
27 Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma Completed NCT00116597 Phase 1, Phase 2
28 A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT01636284 Phase 2
29 A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment Completed NCT01387555 Phase 2
30 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
31 Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer Completed NCT00003871 Phase 2
32 Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 Completed NCT00054535 Phase 2
33 A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
34 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
35 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
36 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
37 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
38 A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection Completed NCT02919306 Phase 1, Phase 2 Placebo
39 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
40 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
41 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
42 Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen Completed NCT00019734 Phase 2
43 A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers. Completed NCT01371175 Phase 2
44 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
45 A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
46 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
47 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
48 Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. Completed NCT01666925 Phase 2
49 Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection Completed NCT01658696 Phase 2
50 A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors Completed NCT00003125 Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

MalaCards organs/tissues related to Vaccinia:

41
T Cells, Prostate, Skin, Testes, Breast, Liver, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

19
Skin

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 13243)
# Title Authors PMID Year
1
Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. 38
31142183 2019
2
Vaccinia-related kinase 2 plays a critical role in microglia-mediated synapse elimination during neurodevelopment. 38
31050055 2019
3
Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity. 38
31384667 2019
4
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism. 38
31011628 2019
5
Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function. 38
31236440 2019
6
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. 38
31428674 2019
7
mTOR Dysregulation by Vaccinia Virus F17 Controls Multiple Processes with Varying Roles in Infection. 38
31118254 2019
8
Expression and Purification of Vaccinia Virus DNA Topoisomerase IB Produced in the Silkworm-Baculovirus Expression System. 38
31165966 2019
9
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. 38
31426803 2019
10
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes. 38
31401821 2019
11
Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus). 38
31427778 2019
12
Vaccinia Virus Strain MVA can Induce Optimal CD8+ T cell responses to Directly Primed Antigens Depending on Vaccine Design. 38
31375596 2019
13
Suppressors of Cytokine Signaling and Protein Inhibitors of Activated Signal Transducer and Activator of Transcriptions As Therapeutic Targets in Flavivirus Infections. 38
31436502 2019
14
Successful establishment of a reverse genetic system for QX-type infectious bronchitis virus and technical improvement of the rescue procedure. 38
31430502 2019
15
Neuroprotective effects of neurotropin in a mouse model of hypoxic-ischemic brain injury. 38
31115666 2019
16
Tungsten carbide nanoparticles show a broad spectrum virucidal activity against enveloped and non-enveloped model viruses using a guideline-standardized in vitro test. 38
31436888 2019
17
WIPF2 promotes Shigella flexneri actin-based motility and cell-to-cell spread. 38
31414511 2019
18
Poxviral E3L ortholog (Viral Interferon resistance gene) of orf viruses of sheep and goats indicates species-specific clustering with heterogeneity among parapoxviruses. 38
30991229 2019
19
Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems. 38
31399106 2019
20
Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. 38
31399277 2019
21
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. 38
31110074 2019
22
A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model. 38
31331770 2019
23
Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. 38
31262449 2019
24
Corrigendum to "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles" [Virology 507 (2017) 242-256]. 38
31178060 2019
25
Loss of Cajal bodies in motor neurons from patients with novel mutations in VRK1. 38
31090908 2019
26
The Vaccinia B1 and Cellular VRK2 Kinases Promote Vaccinia Replication Factory Formation through Phosphorylation Dependent Inhibition of Vaccinia B12. 38
31341052 2019
27
CD69 targeting enhances anti-Vaccinia virus immunity. 38
31315995 2019
28
Asparagine Is a Critical Limiting Metabolite for Vaccinia Virus Protein Synthesis during Glutamine Deprivation. 38
30996100 2019
29
Nanoscale polarization of the entry fusion complex of vaccinia virus drives efficient fusion. 38
31285583 2019
30
Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy. 38
31087190 2019
31
A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection. 38
30996093 2019
32
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. 38
31068425 2019
33
Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. 38
31276466 2019
34
Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs. 38
31294846 2019
35
Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. 38
31346211 2019
36
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. 38
31315671 2019
37
Primary human B cells at different differentiation and maturation stages exhibit distinct susceptibilities to vaccinia virus binding and infection. 38
31292245 2019
38
Improved translation efficiency of therapeutic mRNA. 38
31063797 2019
39
HIV C.1086 Envelope Gp140 Protein Boosts Following DNA/MVA Vaccination Fail to Enhance Heterologous Anti-V1V2 Antibody Response and Protection Against Clade C SHIV Challenge. 38
31341049 2019
40
A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. 38
31324890 2019
41
Identification of CP77 as the Third Orthopoxvirus SAMD9 and SAMD9L Inhibitor with Unique Specificity for a Rodent SAMD9L. 38
30918078 2019
42
lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer. 38
31011626 2019
43
Novel VRK1 Mutations in a Patient with Childhood-onset Motor Neuron Disease. 38
31178479 2019
44
Oncolytic Vaccinia Virus Expressing Aphrocallistes vastus Lectin as a Cancer Therapeutic Agent. 38
31248066 2019
45
A single administration of Neurotropin reduced the elongated immobility time in the forced swimming test of rats exposed to repeated cold stress. 38
31188139 2019
46
Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats. 38
31240620 2019
47
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. 38
30885937 2019
48
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. 38
31127039 2019
49
Outbreak of Vaccinia Virus Infection from Occupational Exposure, China, 2017. 38
31107220 2019
50
Poxvirus oncolytic virotherapy. 38
30919708 2019

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 VRK3 TANK NLRP1 IRF7 IRF3 IL2
2
Show member pathways
12.74 TANK NLRP1 IRF7 IRF3 IL2
3
Show member pathways
12.39 TBKBP1 TANK IRF7 IRF3 AZI2
4
Show member pathways
11.87 TANK IRF7 CUL1 BTRC
5 11.61 TBKBP1 TANK NLRP1 IRF7 IRF3 IL2
6
Show member pathways
10.85 VRK2 VRK1 BANF1
7
Show member pathways
10.49 IRF7 IRF3 EIF2AK2

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 WASHC2C VRK1 TANK NLRP1 ITSN1 IRF7

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 NLRP1 IRF7 IRF3 IL2 EIF2AK2
2 innate immune response GO:0045087 9.88 TBKBP1 NLRP1 IRF7 IRF3 EIF2AK2
3 peptidyl-serine phosphorylation GO:0018105 9.73 VRK3 VRK2 VRK1
4 response to virus GO:0009615 9.7 IRF7 EIF2AK2 BANF1
5 peptidyl-threonine phosphorylation GO:0018107 9.58 VRK3 VRK2 VRK1
6 NIK/NF-kappaB signaling GO:0038061 9.55 CUL1 BTRC
7 positive regulation of kinase activity GO:0033674 9.54 ITSN1 IL2
8 positive regulation of interferon-alpha production GO:0032727 9.49 IRF7 IRF3
9 regulation of type I interferon production GO:0032479 9.46 IRF7 IRF3
10 viral process GO:0016032 9.44 VRK2 TBKBP1 TANK NLRP1 ITSN1 IRF7
11 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.43 IRF7 IRF3
12 mitotic nuclear envelope reassembly GO:0007084 9.37 VRK1 BANF1
13 type I interferon biosynthetic process GO:0045351 9.32 IRF7 IRF3
14 MDA-5 signaling pathway GO:0039530 9.26 IRF7 IRF3
15 interferon-alpha production GO:0032607 9.16 IRF7 AZI2
16 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.13 TANK IRF7 IRF3

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 WASHC2C VRK3 VRK2 VRK1 TBKBP1 TANK
2 kinase activator activity GO:0019209 8.96 ITSN1 IL2

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....